https://www.selleckchem.com/pr....oducts/5-chloro-2-de
To evaluate the diagnostic performance of F-FDG PET/MR in detecting recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC) who have increased thyroglobulin (Tg) levels but a negative I whole-body scan (WBS). The relationship between F-FDG PET/MR and serum Tg levels was explored. We also evaluated the therapeutic impact of PET/MR on patient clinical management. Twenty-nine DTC patients with a negative I-WBS of the last post-therapeutic and increased Tg levels under thyroid-stimulating hormone
Like
Comment
Share
